Cargando…

Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer

BACKGROUND: Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha, PIK3CA, is one of the most frequently mutated genes in breast cancer, and the mutation status of PIK3CA has clinical relevance related to response to therapy. The aim of our study was to investigate the mutation sta...

Descripción completa

Detalles Bibliográficos
Autores principales: Arsenic, Ruza, Treue, Denise, Lehmann, Annika, Hummel, Michael, Dietel, Manfred, Denkert, Carsten, Budczies, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4652376/
https://www.ncbi.nlm.nih.gov/pubmed/26587011
http://dx.doi.org/10.1186/s12907-015-0020-6
_version_ 1782401740949159936
author Arsenic, Ruza
Treue, Denise
Lehmann, Annika
Hummel, Michael
Dietel, Manfred
Denkert, Carsten
Budczies, Jan
author_facet Arsenic, Ruza
Treue, Denise
Lehmann, Annika
Hummel, Michael
Dietel, Manfred
Denkert, Carsten
Budczies, Jan
author_sort Arsenic, Ruza
collection PubMed
description BACKGROUND: Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha, PIK3CA, is one of the most frequently mutated genes in breast cancer, and the mutation status of PIK3CA has clinical relevance related to response to therapy. The aim of our study was to investigate the mutation status of PIK3CA gene and to evaluate the concordance between NGS and SGS for the most important hotspot regions in exon 9 and 20, to investigate additional hotspots outside of these exons using NGS, and to correlate the PIK3CA mutation status with the clinicopathological characteristics of the cohort. METHODS: In the current study, next-generation sequencing (NGS) and Sanger Sequencing (SGS) was used for the mutational analysis of PIK3CA in 186 breast carcinomas. RESULTS: Altogether, 64 tumors had PIK3CA mutations, 55 of these mutations occurred in exons 9 and 20. Out of these 55 mutations, 52 could also be detected by Sanger sequencing resulting in a concordance of 98.4 % between the two sequencing methods. The three mutations missed by SGS had low variant frequencies below 10 %. Additionally, 4.8 % of the tumors had mutations in exons 1, 4, 7, and 13 of PIK3CA that were not detected by SGS. PIK3CA mutation status was significantly associated with hormone receptor-positivity, HER2-negativity, tumor grade, and lymph node involvement. However, there was no statistically significant association between the PIK3CA mutation status and overall survival. CONCLUSIONS: Based on our study, NGS is recommended as follows: 1) for correctly assessing the mutation status of PIK3CA in breast cancer, especially for cases with low tumor content, 2) for the detection of subclonal mutations, and 3) for simultaneous mutation detection in multiple exons. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12907-015-0020-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4652376
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46523762015-11-20 Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer Arsenic, Ruza Treue, Denise Lehmann, Annika Hummel, Michael Dietel, Manfred Denkert, Carsten Budczies, Jan BMC Clin Pathol Research Article BACKGROUND: Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha, PIK3CA, is one of the most frequently mutated genes in breast cancer, and the mutation status of PIK3CA has clinical relevance related to response to therapy. The aim of our study was to investigate the mutation status of PIK3CA gene and to evaluate the concordance between NGS and SGS for the most important hotspot regions in exon 9 and 20, to investigate additional hotspots outside of these exons using NGS, and to correlate the PIK3CA mutation status with the clinicopathological characteristics of the cohort. METHODS: In the current study, next-generation sequencing (NGS) and Sanger Sequencing (SGS) was used for the mutational analysis of PIK3CA in 186 breast carcinomas. RESULTS: Altogether, 64 tumors had PIK3CA mutations, 55 of these mutations occurred in exons 9 and 20. Out of these 55 mutations, 52 could also be detected by Sanger sequencing resulting in a concordance of 98.4 % between the two sequencing methods. The three mutations missed by SGS had low variant frequencies below 10 %. Additionally, 4.8 % of the tumors had mutations in exons 1, 4, 7, and 13 of PIK3CA that were not detected by SGS. PIK3CA mutation status was significantly associated with hormone receptor-positivity, HER2-negativity, tumor grade, and lymph node involvement. However, there was no statistically significant association between the PIK3CA mutation status and overall survival. CONCLUSIONS: Based on our study, NGS is recommended as follows: 1) for correctly assessing the mutation status of PIK3CA in breast cancer, especially for cases with low tumor content, 2) for the detection of subclonal mutations, and 3) for simultaneous mutation detection in multiple exons. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12907-015-0020-6) contains supplementary material, which is available to authorized users. BioMed Central 2015-11-18 /pmc/articles/PMC4652376/ /pubmed/26587011 http://dx.doi.org/10.1186/s12907-015-0020-6 Text en © Arsenic et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Arsenic, Ruza
Treue, Denise
Lehmann, Annika
Hummel, Michael
Dietel, Manfred
Denkert, Carsten
Budczies, Jan
Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer
title Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer
title_full Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer
title_fullStr Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer
title_full_unstemmed Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer
title_short Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer
title_sort comparison of targeted next-generation sequencing and sanger sequencing for the detection of pik3ca mutations in breast cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4652376/
https://www.ncbi.nlm.nih.gov/pubmed/26587011
http://dx.doi.org/10.1186/s12907-015-0020-6
work_keys_str_mv AT arsenicruza comparisonoftargetednextgenerationsequencingandsangersequencingforthedetectionofpik3camutationsinbreastcancer
AT treuedenise comparisonoftargetednextgenerationsequencingandsangersequencingforthedetectionofpik3camutationsinbreastcancer
AT lehmannannika comparisonoftargetednextgenerationsequencingandsangersequencingforthedetectionofpik3camutationsinbreastcancer
AT hummelmichael comparisonoftargetednextgenerationsequencingandsangersequencingforthedetectionofpik3camutationsinbreastcancer
AT dietelmanfred comparisonoftargetednextgenerationsequencingandsangersequencingforthedetectionofpik3camutationsinbreastcancer
AT denkertcarsten comparisonoftargetednextgenerationsequencingandsangersequencingforthedetectionofpik3camutationsinbreastcancer
AT budcziesjan comparisonoftargetednextgenerationsequencingandsangersequencingforthedetectionofpik3camutationsinbreastcancer